Streptomyces

Other Names

ActinopycnidiumActinosporangiumChainiaElytrosporangiumKitasatoaMicroellobosporiaMicrostreptosporastreptomycetesStreptoverticillium

Synopsis

Streptomyces: A Comprehensive Reference on a Microbial Source of Bioactive Natural Products

1. Identity and Classification

1.1 Taxonomic Position

Streptomyces belongs to the Bacteria domain, the phylum Actinobacteria, the class Actinobacteria, the order Streptomycetes, and the family Streptomycetaceae. The genus was proposed by Waksman and Henrici in 1943 and was classified initially on the basis of morphology (color of hyphae and spores), chemotype, whole-cell sugars, fatty acid and phospholipid profiles, and composition of cell wall (peptidoglycan type), and later on the basis of phenotypic and genotypic traits. The phylum Actinobacteria (recently proposed to be renamed Actinomycetota) is a group of high G+C bacteria that includes multicellular filamentous bacteria such as Streptomyces species.

1.2 Morphology

Like Actinomyces and Propionibacterium, Streptomyces belongs to the large group of filamentous bacteria known as actinomycetes, but Streptomyces species have a well-developed substrate mycelium, produce an aerial mycelium with chains of spores, and are strict aerobes. They form a threadlike net called a mycelium that bears chains of spores at maturity. Their branching strands are 0.5 to 1.0 micrometres in diameter. Streptomyces species are characterized as aerobic, Gram-positive, filamentous bacteria which form branched substrate mycelium and aerial hyphae. Members of the genus have a high G+C content and contain the diagnostic ll-diaminopimelic acid in the cell-wall peptidoglycan.

1.3 Life Cycle

The Streptomyces life cycle begins with spore germination and outgrowth into a saprophytic, substrate mycelium which grows by hyphal tip extension and branches through the soil, releasing exoenzymes to break down complex organic polymers such as chitin, lignin, and cellulose. Stress signals, including nutrient starvation, trigger the formation of aerial hyphae, reproductive structures which undergo rapid DNA replication and cell division to form chains of unigenomic spores.

1.4 Ecological Distribution and Natural Habitat

Streptomyces is a genus of filamentous bacteria of the family Streptomycetaceae (order Actinomycetales) that includes more than 500 species occurring in soil and water. Many species are important in the decomposition of organic matter in soil, contributing in part to the earthy odour of soil and decaying leaves and to the fertility of soil. Streptomyces represents 50% of the total population of soil actinobacteria. Streptomyces, a well-studied genus of Gram-positive bacteria, belongs to the phylum Actinobacteria. These bacteria present a strikingly similar lifestyle to that of filamentous fungi and, like those, most streptomycetes live as saprophytes in the soil. They also successfully inhabit a wide range of other terrestrial and aquatic niches, and some strains are plant and animal pathogens.

The characteristic earthy smell of freshly turned soil is partly attributable to a volatile compound, geosmin, which is produced by Streptomyces species. These metabolites help the vegetative bacterial cells by sequestering metals such as iron (siderophores), protecting them from UV light (through pigmentation), inhibiting competitors (antibiotics), and also facilitating communication with other species.

1.5 Genomic Characteristics

This molecular diversity is possible in Streptomyces through their comparatively large genome, which can be quadruple the size of some other bacterial genomes. One of the unique features of Streptomyces genomes is the wealth of secondary metabolites biosynthetic gene clusters (BGCs) that encode the protein machinery responsible for the production of secondary metabolites with a variety of chemotypes, including polyketides, lactams, terpenes, and nonribosomal peptides.

1.6 Common Forms and Preparations

Streptomyces is not typically consumed as a whole organism in supplement form in the manner of conventional dietary supplements such as herbal extracts. Rather, it is encountered in several principal contexts: (1) as a source organism from which purified or semi-purified bioactive metabolites are derived and developed into pharmaceutical drugs; (2) as a fermentation-based ingredient or probiotic candidate in emerging research; and (3) historically, as a constituent of mineral-rich soils used therapeutically in various cultures. The nutritional conditions under which Streptomyces are cultivated affects their antibiotic production. Many traditional medicines are applied in their raw state, usually incorporating some of the original isolation material, which can be chemically quite complex.

2. Traditional and Historical Use

2.1 Ancient and Indigenous Soil-Based Remedies

One of the earliest connections between Streptomyces and traditional medicine is the Red Soil of Jordan, which has been used as a cure for skin infections for millennia. More definitive connections have been found in Africa, where researchers discovered that some ancient Nubian bones (~300 [AD]) contained tetracycline residues. This finding has been interpreted as evidence that populations in the ancient Nubian kingdom ingested tetracyclines — compounds naturally produced by Streptomyces — potentially through fermented grain preparations or through contact with soils rich in antibiotic-producing actinomycetes.

Many traditional medicines containing Streptomyces are associated with extreme environments typically low in nutrients, such as deserts, high altitudes, salt plains, or cold areas, where these bacteria form symbiotic associations with indigenous flora. Streptomyces currently provides many of the world's clinical antibiotics, so it comes as no surprise that these bacteria have recently been isolated from traditional medicine.

2.2 Traditional Irish Soil Cure

A well-documented ethnomedicinal use involves a soil from the West Fermanagh Scarplands in Ireland, traditionally believed to have healing properties against infection. Streptomyces from a traditional soil cure in the West Fermanagh Scarplands was cultivated on selective isolation agar, yielding Streptomyces sp. myrophorea, which inhibited MRSA, as evidenced by a clear zone of inhibition. This finding provided a scientific basis for a traditional belief that had persisted for generations, demonstrating that the bioactive components of the soil were attributable to resident Streptomyces strains.

2.3 Scientific Formalization: The Waksman Era

Since the discovery of actinomycin in Selman Waksman's laboratory at Rutgers University in 1940, followed in 1943 by streptomycin, the first really effective drug to treat tuberculosis, the actinomycetes have been famous as producers of antibiotics and other "secondary metabolites" with biological activity. The discovery of streptomycin, the first effective antibiotic treatment for tuberculosis, was a pivotal moment in medical history attributed to Dr. Selman Waksman and his team at Rutgers University. Unlike the serendipitous discovery of penicillin, Waksman's work was grounded in a systematic research program exploring the antimicrobial properties of soil microbes, particularly actinomycetes.

In 1943, he and his students isolated streptomycin from the soil bacterium Streptomyces griseus, demonstrating its effectiveness against Mycobacterium tuberculosis, the causative agent of tuberculosis. Waksman won the Nobel Prize for Physiology or Medicine in 1952 for the screening process that led to the discovery of streptomycin and other antibiotics. Selman Abraham Waksman coined the word antibiotic.

During the Golden Age of antibiotic discovery, in the 1950s and 1960s, such well-known antibacterial drugs as tetracycline, erythromycin, and kanamycin, antifungal agents like candicidin and nystatin, and anticancer drugs such as adriamycin were discovered through the efforts of academic and industrial researchers. After 1970, the rate of discovery of useful compounds declined progressively, although several important agents nevertheless came to light, including the antihelmintic avermectin, the immunosuppressants rapamycin and tacrolimus (FK506), and the natural herbicide bialaphos.

3. Key Constituents and Bioactive Secondary Metabolites

3.1 Scope of Production

Streptomyces is the most ubiquitous bacterial genus in the environments with prolific capability to produce diverse and valuable natural products with significant biological activities in medicine, environments, food industries, and agronomy sectors. Streptomyces produce around 100,000 antibiotic compounds, which account for 70–80% of all natural bioactive products with pharmacological or agrochemical applications. The StreptomeDB database's content has been increased to over 4,000 compounds from more than 2,500 host organisms.

The genus Streptomyces alone accounts for a remarkable 80% of the actinobacterial natural products reported to date, a biosynthetic capacity that remains without rival in the microbial world. Streptomyces produce a variety of natural products with high structural diversity, including macrolides, tetracyclines, aminoglycosides, glycopeptides, ansamycins, and terpenes.

3.2 Antibacterial Compounds

Since the late 1940s, Streptomyces species have been recognized as prolific producers of specialized bioactive natural products, especially antibiotics. Over two-thirds of the medically useful antibiotics on the market are sourced from this genus, such as tetracycline, erythromycin, daptomycin, chloramphenicol, streptomycin, and vancomycin.

Streptomycetes are well-studied for their ability to synthesize antibiotics of various classes, which exhibit antibacterial, antifungal, antiviral, antitumor, antihypertensive, and immunosuppressive effects. These include polyene antibiotics (nystatin and amphotericin B, mediomycins A, B, clethramycin, candidine), aminoglycosides (streptomycin and neomycin), macrolides (erythromycin), tetracyclines (tetracycline and oxytetracycline), glycopeptides (vancomycin), and beta-lactams.

These antibiotics have diverse mechanisms of action: the induction of membrane pore formation and ion leakage, the inhibition of protein biosynthesis or DNA replication, the destruction of biological membranes or cell walls, and changes in the metabolism of sensitive cells.

3.3 Antifungal Compounds

Clinically useful natural products originating from Streptomyces are not just confined to antibiotics, but also include antifungals (e.g., amphotericin B), antivirals (e.g., boromycin), and antiparasitics (e.g., ivermectin). Less commonly, streptomycetes produce compounds used in other medical treatments: migrastatin (from S. platensis) and bleomycin (from S. verticillus) are antineoplastic (anticancer) drugs; boromycin (from S. antibioticus) exhibits antiviral activity against the HIV-1 strain of HIV, as well as antibacterial activity.

3.4 Immunosuppressive Compounds: Rapamycin and FK506

FK506 and rapamycin are immunosuppressants that inhibit signalling cascades required for T-cell activation; yet both are natural products of Streptomyces that live in the soil. Rapamycin (sirolimus) is produced by Streptomyces hygroscopicus; FK506 (tacrolimus) is produced by Streptomyces tsukubaensis.

Both rapamycin and tacrolimus can selectively inhibit the proliferation of T-lymphocytes. The pipecolate moiety present in the macrolactone ring of both FK506 and rapamycin binds to the cellular receptor FKBP12, for the inhibition of T-cell proliferation. But both of these possess different modes of action.

The immunosuppressive and antimicrobial activities of FK506 and rapamycin are mediated by binding to the FKBP12 prolyl isomerase, and the resulting FKBP12/FK506 and FKBP12/rapamycin complexes inhibit conserved protein targets, either the phosphatase calcineurin or the TOR (target of rapamycin) kinases, respectively.

The specificity with which these natural products bind the ubiquitous FKBPs to form protein-drug complexes with exquisite specificity for their targets paved the pathway to develop FK506 (tacrolimus) and rapamycin (sirolimus) and their analogs (pimecrolimus, everolimus, temsirolimus) as FDA-approved drugs for transplant recipients, cancer chemotherapy, dermatology, and interventional cardiology.

3.5 Anticancer Compounds

The famous antitumor compounds produced by Streptomyces species being used in human chemotherapy include actinomycin, mitomycin, anthracycline, bleomycin, aureolic acid families, pentostatin, and resistomycin.

Members of this group are producers of clinically useful antitumor drugs such as anthracyclines (aclarubicin, daunomycin, and doxorubicin), peptides (bleomycin and actinomycin D), aureolic acids (mithramycin), enediynes (neocarzinostatin), antimetabolites (pentostatin), carzinophilin, mitomycins, and others.

An antibiotic called bleomycin (BLM) is produced by the bacterium Streptomyces verticillus. It has been used as an anticancer chemotherapeutic drug to treat diseases that can be cured, like germinative tumors and Hodgkin's lymphoma, including squamous cell carcinoma, and induced pulmonary fibrosis. Through its amino-terminal peptide, it can bind to DNA, and when oxygen and iron are present, by stimulating a DNA-Fe-bleomycin complex, it forms free hydroxyl radicals.

Staurosporine (from S. staurosporeus) also has a range of activities from antifungal to antineoplastic via the inhibition of protein kinases.

3.6 Pigments and Antioxidant Compounds

More than 76% of all known bioactive secondary metabolites are derived from actinomycetes, with Streptomyces species producing a broad range of antimicrobial, anticancer, antioxidant, and pigment-forming compounds. In recent years, increasing consumer demand for natural, sustainable ingredients has renewed interest in Streptomyces-derived pigments as alternatives to synthetic dyes in high-value sectors.

3.7 Biosynthetic Pathways

Several studies confirm that Streptomyces are able to produce different antitumor compounds with diverse chemical backbones because they harbor different gene clusters encoding polyketide and nonribosomal peptide synthases. For example, Streptomyces hygroscopicus secretes around 180 metabolites with a wide range of bioactivities. The biosynthetic gene clusters encoding these pathways are housed within the characteristically large Streptomyces genome and include machinery for polyketide synthases (PKS) and nonribosomal peptide synthetases (NRPS), which assemble structurally complex molecules from simple building-block precursors.

4. Scientific Evidence by Area of Health Application

4.1 Antimicrobial Activity

4.1.1 Established Clinical Evidence (Streptomycin and Tuberculosis)

Streptomycin, synthesized by the soil organism Streptomyces griseus, was discovered by American biochemists Selman Waksman, Albert Schatz, and Elizabeth Bugie in 1943. The drug acts by interfering with the ability of a microorganism to synthesize certain vital proteins. It was the first antimicrobial agent developed after penicillin and the first antibiotic effective in treating tuberculosis. Streptomycin was not toxic to animals, and was effective against tuberculosis in guinea pigs and in patients.

Streptomycin's effectiveness against tuberculosis increased when it was used in combination with other drugs, especially with para-aminosalicylic acid and isoniazid. Streptomycin was the "first broad-spectrum, pharmaceutically effective antibiotic attacking both Gram-positive and Gram-negative bacteria in addition to acid-fast bacteria."

Evidence strength: High. Streptomycin has decades of well-controlled clinical use, pharmacopoeial monograph status, and WHO Essential Medicine listing. Its mechanism is firmly established.

4.1.2 Emerging Evidence (Anti-MRSA and Novel Streptomyces Isolates)

Given the increased reporting of multi-resistant bacteria and the shortage of newly approved medicines, researchers have been looking towards extreme and unusual environments as a new source of antibiotics. Streptomyces currently provides many of the world's clinical antibiotics, so it comes as no surprise that these bacteria have recently been isolated from traditional medicine. Laboratory research has identified novel anti-MRSA activity from soil-derived strains, such as Streptomyces sp. myrophorea from the Irish "healing clay." However, these represent early-stage in vitro studies, and no human clinical trials for new anti-MRSA Streptomyces products have been completed.

Evidence strength: Preliminary; in vitro only for most novel isolates. No human randomized controlled trials for newly isolated strains.

4.2 Oncology (Streptomyces-Derived Anticancer Drugs)

The mechanism of action of anticancer bioactive compounds isolated from Streptomyces has been well-documented for several decades. Many of these compounds, such as doxorubicin (DXR) and mitomycin C, are widely used in clinical settings. These agents act primarily through mechanisms such as DNA intercalation, topoisomerase inhibition, and apoptosis induction in cancer cells. While ongoing research explores new derivatives and improved formulations, their established role in oncology remains critical.

Mitomycin C is another anticancer compound that has been isolated from Streptomyces caespitosus. Its chemical structure includes a quinone ring that undergoes reduction under hypoxic conditions and an aziridine ring for alkylation reaction and a carbamoyl group. It is a chemotherapy drug that inhibits DNA synthesis in cancer cells, leading to their death. The exact mechanism of action of mitomycin C is also not fully understood, but it is believed to crosslink the DNA strands, preventing replication and transcription.

For example, doxorubicin is used to treat breast, ovarian, and lung cancer, soft tissue sarcoma, Wilms tumor, and neuroblastoma cancer.

There are many diverse mechanisms by which these compounds are able to control different tumor cells, which include apoptosis, mitochondrial permeabilization, blockage of signal transduction pathways by inhibiting key enzymes, cytomorphological changes due to disturbance in cellular differentiations, and tumor-induced angiogenesis.

Literature search has uncovered the mechanism of action of several cancer bioactive compounds isolated from Streptomyces, including bleomycin (BLM), doxorubicin (DXR), mitomycin C, pladienolides (Plad), platensimycin (PTM), and platencin (PTN). While these compounds have shown anticancer activity, their full therapeutic potential has not been completely studied or tested in human clinical trials.

Evidence strength: High for established drugs (doxorubicin, bleomycin, mitomycin C) in approved clinical indications. For newer Streptomyces-derived candidates (platensimycin, pladienolides), evidence is preliminary and largely preclinical.

4.3 Immunosuppression and Transplant Medicine

FK506 is an FDA-approved immunosuppressive drug utilized to prevent and treat allograft rejection during organ and tissue transplantation. It has been used as an immunosuppressant after the transplantation of allogeneic kidney, liver, and bone marrow as well as for the treatment of inflammatory skin diseases and eczema.

Rapamycin (sirolimus) and its analogs — everolimus and temsirolimus — are Streptomyces-derived macrolides that have expanded indications beyond transplantation. Rapamycin is a multifaceted drug; it has anti-cancer, anti-viral, and anti-aging potentials. Rapamycin has its specific action on the mTOR signaling pathway. mTOR has been identified as a key regulator of different pathways.

Evidence strength: High. Tacrolimus and rapamycin analogs have extensive Phase III clinical trial databases, FDA approval, and decades of post-marketing surveillance.

4.4 Probiotic and Gut Health Applications

The consideration of Streptomyces as a probiotic is an emerging and largely preclinical field. It has been suggested that these microorganisms could be representatives of "past humans," "old friends" that helped to combat allergies and auto-immune and inflammatory diseases, and suppressed colon carcinogenesis through the production of anti-proliferative, anti-inflammatory, and/or immunosuppressant compounds. These authors also suggested that this observation can be explained by the "hygiene hypothesis," which relates to our current lifestyle and reduced exposure to nature. Another cause of reduced Streptomyces in human gut microbiota could be the uncontrolled consumption of antibiotics.

One study was conducted to evaluate the probiotic, antibacterial, and antibiofilm potential of Streptomyces levis strain HFM-2, isolated from the healthy human gut. The study shows that S. levis strain HFM-2 has significant probiotic properties such as good viability in bile, gastric juice, pancreatin environment, and at low pH; proficient adhesion properties; and antibiotic susceptibility. Further, the ethyl acetate extract from S. levis strain HFM-2 showed strong biofilm inhibition against S. typhi, K. pneumoniae, P. aeruginosa, and E. coli. This was an in vitro study; no clinical human trials of Streptomyces as a dietary probiotic have been published.

Therefore, Streptomyces probiotics offer a strategy to increase these microorganisms in the human gut to prevent diseases that are currently more prevalent due to our lifestyle. In addition, it is known that Streptomyces can degrade a large number of chemically synthesized toxic compounds, such as pesticides, that are stable in the environment and become part of the trophic chain.

Evidence strength: Weak/preliminary. All available evidence is from in vitro studies or animal models. There are no published human clinical trials establishing Streptomyces as a safe or effective human probiotic ingredient.

4.5 Agricultural and Veterinary Use

The macrolide antibiotic tylosin, produced naturally by Streptomyces fradiae, is the most commonly used feed additive in the farming industry, applied as a growth promoter and to treat diseases. Streptomyces-derived bioactive natural products have the capability to function as antimicrobial, antiviral, cytotoxic, antitumor, antihypertensive, immunosuppressive, insecticide, antioxidative, plant growth-promoting, and herbicidal agents.

5. Body Systems and Health Areas of Association

Streptomyces and its derived natural products are associated with the following physiological systems and disease areas, primarily through approved pharmaceutical agents or investigational compounds:

Immune system / transplant medicine: Tacrolimus (FK506) and sirolimus (rapamycin) suppress organ rejection; both rapamycin and tacrolimus can selectively inhibit the proliferation of T-lymphocytes.
Oncology / Hematology: Among anticancer substances, doxorubicin, daunomycin, mitomycin C, and bleomycin are all synthesized by Streptomyces.
Infectious disease / Respiratory: Streptomycin remains in use for tuberculosis; other aminoglycosides and macrolides from Streptomyces cover a wide range of bacterial infections.
Dermatology: FK506 is highly used as an immunosuppressant applied in a wide variety of therapeutic applications from facilitating human organ transplants to autoimmune-disease therapies, hypertension, and even ocular diseases.
Gastrointestinal system: Emerging probiotic research positions Streptomyces as a potential gut microbiome contributor, though human evidence is lacking.
Cardiovascular system: Rapamycin-coated coronary stents exploit the anti-proliferative action of sirolimus to prevent in-stent restenosis; this is an approved medical device application.
Neurodegeneration / Aging: Members of the genus Streptomyces have been explored extensively over the past decades as these filamentous bacteria are highly efficient in producing bioactive compounds with human health benefits, including investigation of rapamycin's mTOR-pathway activity in longevity research — though this remains investigational in humans.

6. Dosage Forms and Reported Dosages

Because Streptomyces itself is not commercially formulated as a standardized dietary supplement in the same way as herbal extracts, there are no pharmacopoeially standardized human supplement doses for whole Streptomyces organisms. Dosage information in the scientific literature pertains to purified compounds derived from Streptomyces:

Streptomycin (aminoglycoside antibiotic): Administered parenterally (intramuscularly) in tuberculosis regimens. Dosages are defined by pharmacopoeial monographs and WHO guidelines for specific infectious disease indications; they fall outside the scope of dietary supplementation.
Probiotic research: In in vitro probiotic studies of S. levis HFM-2, MIC and MBC values of the ethyl acetate extract were determined at 500 and 1000 µg/mL, respectively. These concentrations were used in laboratory assays only; no human oral dosage has been established.
Rapamycin (sirolimus): Used clinically in transplant medicine at physician-prescribed doses; the mTOR-inhibitory mechanism is the subject of human longevity trials, but no safe/effective dietary supplement dosage has been established.
Mitomycin C: In humans, mitomycin C is rapidly cleared from the serum after intravenous administration. Time required to reduce the serum concentration by 50% after a 30 mg bolus injection is 17 minutes. This is a clinical oncology drug, not a dietary supplement.

In summary, no established or evidence-backed oral supplemental dosage regimen for Streptomyces as a consumed dietary supplement has been published in peer-reviewed literature as of the time of writing.

7. Safety Considerations and Known Risks

7.1 Pathogenicity: Mostly Saprophytic, Rarely Opportunistic

Most species are not pathogenic. Streptomyces are saprophytic soil organisms rarely known to cause invasive infections other than mycetoma.

The aerobic actinomycetes, including the genera Nocardia, Actinomadura, and Streptomyces, are widely known etiological agents responsible for various spectrum of manifestations including pulmonary, systemic, and cutaneous diseases — that is, mycetoma (swollen tumor-like subcutaneous lesions that yield granular pus through draining sinuses).

Frequent exposure to penetrating wounds by thorns or splinters is a risk factor for mycetoma, especially in combination with contaminated soil material. S. sudanensis represents the major causal agent of actinomycetoma — a largely under-studied and dreadful subcutaneous disease of humans in the tropics and subtropics.

7.2 Invasive Infections in Immunocompromised Individuals

Reported invasive cases have included lung abscess or pneumonitis, central venous catheter-related bloodstream infection, and possible hypersensitivity pneumonitis. Most previous cases also included lung infections and bloodstream infections. Preexisting conditions such as cancer, AIDS or HIV infection, presence of a central venous catheter, and prosthetic heart valve were present in all cases since 1985. Diverse Streptomyces species were involved, consistent with the highly opportunistic nature of the infections.

Streptomyces are environmental gram-positive bacilli that can cause ubiquitous mycetoma and, more rarely, invasive infections. These organisms are present ubiquitously; hence, when grown in a culture of samples collected from patients with chronic cutaneous and subcutaneous diseases, they are often misdiagnosed as environmental contaminants. This not only delays the diagnosis but also appropriate and timely treatment, thereby prolonging the morbidity.

7.3 Antibiotic Resistance Concerns

Because streptomycin was effective against a wide variety of diseases, it was used often, with the result that many initially sensitive microorganisms, including the bacterium that causes tuberculosis, became resistant to the antibiotic. The potential emergence of antibiotic resistance following uncontrolled use of Streptomyces-derived antibiotics is a well-recognized and extensively documented public health concern.

7.4 Gut Microbiome Displacement Concerns

One cause of reduced Streptomyces in human gut microbiota could be the uncontrolled consumption of antibiotics. Conversely, because Streptomyces strains themselves produce antibiotics, oral administration of live Streptomyces could in principle disrupt other commensal gut bacteria — a risk that has not been systematically assessed in human trials.

7.5 Lack of Human Safety Data for Whole-Organism Supplementation

There are no published Phase I or Phase II human safety trials for orally consumed whole-cell Streptomyces preparations as dietary supplements. All available human safety data pertain to highly purified and pharmaceutically processed derivatives (e.g., tacrolimus, doxorubicin, streptomycin), which carry their own well-characterized adverse effect profiles established through clinical drug development programs.

7.6 Geosmin and Sensory Characteristics

Streptomyces species are the principal biological producers of geosmin, a bicyclic sesquiterpene responsible for the characteristic earthy smell of soil. While geosmin itself has no established adverse effects at environmental exposure levels, its presence is an indicator of active Streptomyces populations and can occasionally cause off-flavors in drinking water and agricultural produce when Streptomyces populations are abundant.

References

Health Conditions

Health conditions that Streptomyces may help support.

No conditions available.

Body Systems

Body systems that Streptomyces may help support.

No body systems available.